Biogen (NASDAQ:BIIB) said it continues to expect full-year 2023 adjusted EPS of $15 to $16. Analysts polled by Capital IQ are expecting adjusted EPS of $15.43. Revenue for the year is expected to decline by mid-single-digit percentage from a year earlier.
Biogen (NASDAQ:BIIB) expect full-year 2023 adjusted EPS of $15 to $16 Read Post »
Biogen (NASDAQ:BIIB) Q2 Adj. EPS $4.20 vs FactSet Consensus $3.77.
Biogen (NASDAQ:BIIB) Q2 Adj. EPS $4.20 vs FactSet Consensus $3.77 Read Post »
Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $363 to $381.
Morgan Stanley raises Biogen (NASDAQ:BIIB) price target from $363 to $381 Read Post »
Truist Securities analyst Robyn Karnauskas maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $350 to $340.
Truist Securities lowers Biogen (NASDAQ:BIIB) price target from $350 to $340 Read Post »
Barclays Adjusts Biogen (NASDAQ:BIIB) Price Target to $294 From $311, Maintains Equal Weight Rating.
Barclays Adjusts Biogen (NASDAQ:BIIB) Price Target to $294 From $311 Read Post »
Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:BIIB) with a Overweight and lowers the price target from $350 to $343.
Wells Fargo lowers Biogen (NASDAQ:BIIB) price target from $350 to $343 Read Post »
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $379 to $374.
RBC Capital lowers Biogen (NASDAQ:BIIB) price target from $379 to $374 Read Post »
Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $320 price target.
Needham maintains Biogen (NASDAQ:BIIB) $320 price target Read Post »
Stifel analyst Paul Matteis maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $324 to $320.
Stifel lowers Biogen (NASDAQ:BIIB) price target from $324 to $320 Read Post »
Biogen (NASDAQ:BIIB) reported Q2 non-GAAP earnings of $4.02 per diluted share, down from $5.25 a year earlier. Analysts polled by Capital IQ expected $3.76. Total revenue for the quarter ended June 30 was $2.46 billion, down from $2.59 billion a year earlier. Analysts surveyed by Capital IQ expected $2.36 billion. Biogen said it continues to expect full-year 2023 adjusted EPS of $15 to $16. Analysts polled by Capital IQ are expecting adjusted EPS of $15.43. Revenue for the year is expected to decline by mid-single-digit percentage from a year earlier.
Oppenheimer Adjusts Biogen (NASDAQ:BIIB) Price Target to $350 From $325, Maintains Outperform Rating.
Oppenheimer Adjusts Biogen (NASDAQ:BIIB) Price Target to $350 From $325 Read Post »
Argus Research analyst Jasper Hellweg maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $320 to $350.
Argus Research raised Biogen (NASDAQ:BIIB) price target from $320 to $350 Read Post »